Director at Acrivon Therapeutics (ACRV) awarded 9,366 RSUs vesting 2027

Rhea-AI Filing Summary

Shacham Sharon reported acquisition or exercise transactions in this Form 4 filing.

Acrivon Therapeutics director Sharon Shacham received an equity grant in the form of restricted stock units. The award covers 9,366 RSUs, each representing a right to receive one share of Acrivon common stock at no purchase price. These RSUs vest in full on May 18, 2027, provided she remains in continuous service through that date. Following this grant, her reported direct holdings total 9,366 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Shacham Sharon

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	9,366	$0.00	--

Holdings After Transaction: Common Stock — 9,366 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSUs granted: 9,366 units Grant price: $0.00 per share Vesting date: May 18, 2027 +1 more

4 metrics

RSUs granted 9,366 units Restricted stock units awarded to director on May 18, 2026

Grant price $0.00 per share RSUs granted at no purchase price

Vesting date May 18, 2027 RSUs vest in full on this date if service continues

Shares after transaction 9,366 shares Total direct holdings following the RSU grant

Key Terms

restricted stock units ("RSUs"), contingent right, continuous service

3 terms

restricted stock units ("RSUs") financial

"These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right..."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents a contingent right to receive one share of the Issuer's Common Stock."

continuous service financial

"These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service..."

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Shacham Sharon

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/18/2026		A(1)		9,366	A	$0	9,366	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares represent restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. These RSUs shall vest in full on May 18, 2027, subject to the Reporting Person's continuous service through such vesting date.

	/s/ Adam D. Levy, Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Acrivon Therapeutics (ACRV) disclose in this Form 4 for Sharon Shacham?

The filing shows director Sharon Shacham received 9,366 restricted stock units. Each RSU converts into one share of common stock, subject to vesting conditions, as part of her equity-based compensation from Acrivon Therapeutics.

How many Acrivon Therapeutics (ACRV) RSUs were granted to Sharon Shacham?

Sharon Shacham was granted 9,366 restricted stock units. Each RSU represents a contingent right to receive one share of Acrivon Therapeutics common stock, giving her a potential future equity stake of 9,366 shares upon vesting.

When do Sharon Shacham’s Acrivon (ACRV) RSUs vest?

All 9,366 RSUs granted to Sharon Shacham vest in full on May 18, 2027. Vesting requires her continuous service with Acrivon Therapeutics through that date, meaning she must remain in an eligible role until then to receive the shares.

Did Sharon Shacham buy or sell Acrivon Therapeutics (ACRV) stock in this Form 4?

The Form 4 reports an acquisition through a grant, not a market trade. Sharon Shacham received 9,366 RSUs at no purchase price as compensation, with no open-market buying or selling of Acrivon Therapeutics shares disclosed in this filing.

How many Acrivon Therapeutics (ACRV) shares does Sharon Shacham hold after this grant?

After the RSU award, Sharon Shacham’s reported direct holdings total 9,366 shares. These reflect the equity position shown in the Form 4, tied to the granted RSUs and subject to their vesting terms on May 18, 2027.